FDA Warns of PML Case With Gilenya

FDA Warns of PML Case With Gilenya

SILVER SPRING, Md. — A patient being treated for multiple sclerosis and who had no history of using natalizumab (Tysabri) developed progressive multifocal leukoencephalopathy (PML) while taking fingolimod (Gilenya), the FDA said. "This is the first

2
Like
Save

Comments

Write a comment

*